AstraZeneca Past Earnings Performance
Past criteria checks 1/6
AstraZeneca has been growing earnings at an average annual rate of 29.2%, while the Pharmaceuticals industry saw earnings growing at 1.2% annually. Revenues have been growing at an average rate of 16.2% per year. AstraZeneca's return on equity is 15.9%, and it has net margins of 12.7%.
Key information
29.2%
Earnings growth rate
24.4%
EPS growth rate
| Pharmaceuticals Industry Growth | 6.0% |
| Revenue growth rate | 16.2% |
| Return on equity | 15.9% |
| Net Margin | 12.7% |
| Next Earnings Update | 06 Feb 2025 |
Recent past performance updates
No updates
Recent updates
AstraZeneca: Strong Growth Potential And Market Volatility Offer Opportunity
Nov 13AstraZeneca: Contrarian Buy After The China Challenge (Rating Upgrade)
Nov 07AstraZeneca: Buy This Big Pharma Stock At A Discount Now
Sep 24AstraZeneca: Dato-DXd Should Still Be Approved In Q4 Despite Underwhelming Data
Sep 12Revenue & Expenses Breakdown
How AstraZeneca makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 51,206 | 6,495 | 18,081 | 11,477 |
| 30 Jun 24 | 49,133 | 6,440 | 18,268 | 10,955 |
| 31 Mar 24 | 47,611 | 6,331 | 18,365 | 10,662 |
| 31 Dec 23 | 45,811 | 5,955 | 18,025 | 10,299 |
| 30 Sep 23 | 44,994 | 5,896 | 18,258 | 9,922 |
| 30 Jun 23 | 44,485 | 6,163 | 17,732 | 9,782 |
| 31 Mar 23 | 43,840 | 4,705 | 17,425 | 9,642 |
| 31 Dec 22 | 44,351 | 3,288 | 17,422 | 9,529 |
| 30 Sep 22 | 45,155 | 2,040 | 17,425 | 9,134 |
| 30 Jun 22 | 44,038 | -1,253 | 17,232 | 9,184 |
| 31 Mar 22 | 41,487 | -1,063 | 15,623 | 8,535 |
| 31 Dec 21 | 37,417 | 112 | 14,673 | 8,049 |
| 30 Sep 21 | 32,816 | 1,471 | 13,651 | 7,831 |
| 30 Jun 21 | 29,528 | 3,771 | 12,270 | 6,888 |
| 31 Mar 21 | 27,583 | 3,977 | 11,808 | 6,448 |
| 31 Dec 20 | 26,617 | 3,196 | 11,586 | 5,901 |
| 30 Sep 20 | 25,871 | 2,497 | 10,909 | 5,653 |
| 30 Jun 20 | 25,699 | 2,148 | 11,367 | 5,504 |
| 31 Mar 20 | 25,247 | 1,522 | 11,652 | 5,471 |
| 31 Dec 19 | 24,384 | 1,335 | 11,438 | 5,349 |
| 30 Sep 19 | 24,137 | 2,056 | 12,134 | 5,442 |
| 30 Jun 19 | 23,071 | 2,188 | 11,317 | 5,338 |
| 31 Mar 19 | 22,403 | 2,408 | 10,880 | 5,313 |
| 31 Dec 18 | 22,090 | 2,155 | 10,822 | 5,299 |
| 30 Sep 18 | 21,450 | 2,422 | 9,850 | 5,251 |
| 30 Jun 18 | 22,342 | 2,677 | 9,885 | 5,378 |
| 31 Mar 18 | 22,238 | 2,804 | 9,625 | 5,358 |
| 31 Dec 17 | 22,465 | 3,001 | 9,406 | 5,455 |
| 30 Sep 17 | 22,273 | 3,542 | 9,251 | 5,507 |
| 30 Jun 17 | 21,740 | 3,870 | 9,049 | 5,501 |
| 31 Mar 17 | 22,292 | 3,390 | 9,645 | 5,586 |
| 31 Dec 16 | 23,002 | 3,499 | 9,743 | 5,679 |
| 30 Sep 16 | 23,816 | 2,465 | 10,464 | 5,790 |
| 30 Jun 16 | 24,062 | 2,221 | 10,784 | 5,800 |
| 31 Mar 16 | 24,766 | 2,921 | 10,796 | 5,808 |
| 31 Dec 15 | 24,708 | 2,825 | 11,024 | 5,660 |
| 30 Sep 15 | 25,025 | 1,696 | 11,796 | 5,392 |
| 30 Jun 15 | 25,689 | 1,180 | 12,255 | 5,361 |
| 31 Mar 15 | 26,144 | 1,279 | 12,280 | 5,180 |
| 31 Dec 14 | 26,547 | 1,233 | 12,219 | 5,001 |
| 30 Sep 14 | 26,675 | 1,030 | 11,601 | 4,975 |
| 30 Jun 14 | 26,316 | 2,022 | 10,977 | 4,438 |
| 31 Mar 14 | 25,786 | 2,049 | 10,476 | 4,428 |
| 31 Dec 13 | 25,806 | 2,556 | 10,057 | 4,281 |
Quality Earnings: AZN has a large one-off loss of $4.5B impacting its last 12 months of financial results to 30th September, 2024.
Growing Profit Margin: AZN's current net profit margins (12.7%) are lower than last year (13.1%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: AZN's earnings have grown significantly by 29.2% per year over the past 5 years.
Accelerating Growth: AZN's earnings growth over the past year (10.2%) is below its 5-year average (29.2% per year).
Earnings vs Industry: AZN earnings growth over the past year (10.2%) did not outperform the Pharmaceuticals industry 54.6%.
Return on Equity
High ROE: AZN's Return on Equity (15.9%) is considered low.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 08:51 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
AstraZeneca PLC is covered by 80 analysts. 24 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Peter Ankersen | ABG Sundal Collier |
| Kamla Singh | AlphaValue |
| John Eade | Argus Research Company |